News | Artificial Intelligence | May 12, 2021

NICE Renews Support for Use of AI-powered HeartFlow Analysis

The digital technology is reducing reliance on unnecessary invasive diagnostic procedures and is cutting hospital waiting times

The digital technology is reducing reliance on unnecessary invasive diagnostic procedures and is cutting hospital waiting times

May 12, 2021 — HeartFlow, Inc., a leader in revolutionizing precision heartcare, today announced that the National Institute of Health and Care Excellence (NICE) has renewed its support for the use of its AI-powered HeartFlow FFRct Analysis to fight coronary heart disease (CHD), one of the leading causes of death in the UK.

NICE has found that the HeartFlow Analysis continues to improve patient experience and reduce the need for invasive angiography, four years after its initial recommendation that the technology be used to support CHD diagnosis within the NHS. Furthermore, it has estimated that using the HeartFlow Analysis represents a cost saving of £391 per patient to NHS England, £177 higher than original calculations suggested in 2017.

The latest guidance represents a win for the use of digital technologies in the NHS and reflects its commitment to improving patient care through innovation. The HeartFlow Analysis was recently selected as one of the innovations supported by NHS England’s new MedTech Funding Mandate, which aims to provide new medical devices and digital products to patients faster.

NICE also recognises the non-invasive technology’s improved performance in recent years, including:

  • Ongoing incremental software releases to address security updates, compatibility updates and user experience improvements based on clinician feedback;
  • A reduced turnaround time for sharing findings of the Analysis with clinicians - from 48 hours in 2017 to six hours;
  • Enhanced options for viewing the 3D model, such as via mobile platforms, integration with electronic health records and shared patient management updates.

Tim Fairbairn, M.D., Consultant Cardiologist, at Liverpool Heart & Chest Hospital and honorary senior lecturer at the University of Liverpool Hospitals said: “This latest assessment from NICE that the HeartFlow technology offers significant cost savings through avoidance of invasive investigations and streamlining treatment for patients reinforces what we have been seeing in clinical practice. In light of that, we’re pleased to continue its use within the healthcare service at Liverpool Heart and Chest Hospital where it is helping improve our care of CHD patients.”

The HeartFlow Analysis streamlines the diagnostic experience for patients – often enabling physicians to eliminate invasive diagnostic procedures for those who do not need them. It also helps physicians swiftly and accurately diagnose those who do need invasive procedures. The technology limits redundant non-invasive diagnostic testing, reduces patient time in hospital and face-to-face clinical contact, and helps ensure that hospital visits for those who do need them are streamlined, which is particularly crucial during the Covid-19 pandemic

Campbell Rogers, M.D., Executive Vice President and Chief Medical Officer, HeartFlow, said: “It’s fantastic to see the renewed guidance from NICE which continues to advocate a CTA-first approach to diagnosing CHD. The HeartFlow Analysis has been identified as a best practice, non-invasive option for patients with stable, recent onset chest pain. It helps clinicians to make a diagnosis more confidently, while reducing the time to diagnosis for patients.

“The HeartFlow Analysis is now available in 65 NHS hospitals across England and is planned to be in 30 more by 2022. With the support of NICE and as part of NHSE’s MedTech Funding Mandate, we’re now in a position to scale and ensure that more clinicians and patients can benefit from our non-invasive technology and receive a quicker CHD diagnosis and treatment plan," he continued.

About the HeartFlow FFRct Analysis

The HeartFlow Analysis is a non-invasive, cardiac test for stable symptomatic patients with CAD, the leading cause of death worldwide. Starting with a standard coronary CTA, the HeartFlow Analysis leverages deep learning and highly trained analysts to create a digital, personalized 3D model of the heart. The HeartFlow Analysis then uses powerful computer algorithms to solve millions of complex equations to simulate blood flow and provides FFRct values along the coronary arteries. This information helps physicians evaluate the impact a blockage may be having on blood flow and determine the optimal course of treatment for each patient. A positive FFRct value (≤0.80) indicates that a coronary blockage is impeding blood flow to the heart muscle to a degree which may warrant invasive management.

Data demonstrating the safety, efficacy and cost-effectiveness of the HeartFlow Analysis have been published in more than 425 peer-reviewed publications, including long-term data out to five years. The HeartFlow Analysis offers the highest diagnostic performance available from a non-invasive test. To date, clinicians around the world have used the HeartFlow Analysis for more than 75,000 patients to aid in the diagnosis of heart disease.

For more information: www.heartflow.com

Related Content

An example of artificial intelligence on the GE Healthcare Vivid E95 system shown at ASE 2019 where the AI automatically pulls in an exam, identifies the left ventricle and myocardial boards and then calculates all the strain measurements in less than 10 seconds. While AI automation can greatly speed workflow, there are questions about the accuracy of AI for the next step in making diagnoses.  #ASE #ASE21 #ASE2021 #AI

An example of artificial intelligence on the GE Healthcare Vivid E95 system shown at ASE 2019 where the AI automatically pulls in an exam, identifies the left ventricle and myocardial boards and then calculates all the strain measurements in less than 10 seconds. While AI automation can greatly speed workflow, there are questions about the accuracy of AI for the next step in making diagnoses. 

Feature | Artificial Intelligence | September 08, 2021 | By Dave Fornell, Editor
Artificial intelligence is becoming best practice to support clinical decisions and help standardize echocardiography analysis for practices. AI, trained on millions of outcome-based data, can provide automation for operators to obtain highly accurate and precise measurements, to better detect and predict cardiovascular disease.
Webinar | Artificial Intelligence | August 12, 2021
Artificial intelligence is becoming best practice to support clinical decisions and help standardize echocardiography
An example of Viz.AI's pulmonary embolism AI application and mobile alert to the physician on-call. Viz.AI and Avicenna.AI Partner to Launch Artificial Intelligence Care Coordination for Pulmonary Embolism and Aortic Disease

An example of Viz.AI's pulmonary embolism AI application and mobile alert to the physician on-call.

News | Artificial Intelligence | July 21, 2021
July 21, 2021 — Artificial int...
Circle Cardiovascular Imaging Partners With DiA Imaging Analysis to Deliver AI-Based Cardiovascular Imaging Solutions
News | Artificial Intelligence | June 28, 2021
June 28, 2021 — Circle Cardiovascular Imaging Inc. and DiA Imaging Analysis Ltd.
Point of care ultrasound, POCUS, combined with artificial intelligence, can help improve echo image quality by inexperienced sonographers.

Getty Images

News | Artificial Intelligence | June 25, 2021
June 25, 2021 – COVID-19 changed everything in healthcare, and a benefit from this pandemic was a surge in innovation
GE is integrating artificial intelligence into most of its imaging and information technology software. AI can aid fast critical care decision making. Above left is the vScan Air wireless point-of-care ultrasound system. It integrates AI for immediate, automated assessment of a patient's ejection fraction, right.

GE is integrating artificial intelligence into most of its imaging and information technology software. AI can aid fast critical care decision making. Above left is the vScan Air wireless point-of-care ultrasound system. It integrates AI for immediate, automated assessment of a patient's ejection fraction, right.

Feature | Artificial Intelligence | June 10, 2021
The digital transformation of healthcare is underway, but it will advance further and faster if key stakeholders work
AI Med will present its Virtual Clinical Series: Imaging Built by Clinicians, for Clinicians, June 29-30, 2021.
News | Artificial Intelligence | June 09, 2021
June 9, 2021 — AI Med will present its...
The Eko digital stethoscope can record heart soubnds and use an artificial intelligence  (AI) analysis algorithm to detect heart murmurs. I new study in the JAHA showed it has comparable performance to that of an expert cardiologist. Eko Digital Stethoscope AI Analysis Algorithm Validated in JAHA article for Detecting Heart Murmurs

The Eko digital stethoscope can record heart soubnds and use an artificial intelligence  (AI) analysis algorithm to detect heart murmurs. I new study in the JAHA showed it has comparable performance to that of an expert cardiologist.

News | Artificial Intelligence | May 10, 2021
May 10, 2021 — Eko announced the peer-reviewed publication of a clinical study that found that the Eko...